Proponents of government negotiation argue that HHS -- because of its significant purchasing power -- can more effectively negotiate drug prices than individual Part D plans. Opponents argue that allowing the government to negotiate prices for Part D would inhibit innovation and limit beneficiary access to medications.
Read Full Article »
